Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.433
Filtrar
1.
Spectrochim Acta A Mol Biomol Spectrosc ; 264: 120293, 2022 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-34455374

RESUMO

A fluorescence probe based on carbon dots (CDs) coated with silica molecularly imprinted polymer (MIPs) was synthesized for selective and sensitive determination of cetirizine (CTZ). Green source carbon dots were firstly derived from orange peels through a microwave method, and had the merits of eco-friendly and low toxicity. Then a thin silica film was formed on the surface of CDs by reverse microemulsion technique, and molecularly imprinted polymer coated on silica-carbon dots. In this scene, CTZ, 3-aminopropyltriethoxysilane (APTES) and tetraethoxysilane (TEOS) were employed as a template, a functional monomer and cross linker, respectively. The obtained CDs-MIPs can selectively bind CTZ through the specific interaction between recognition sites and template, and obey photoinduced electron transfer fluorescence quenching mechanism. Fluorescence dropped linearly in the range of 0.5-500 ng mL-1, under the optimal conditions, with a detection limit of 0.41 ng mL-1. Furthermore, the proposed method was successfully intended for the determination of trace CTZ in human saliva and urine samples without the interference of other molecules and ions. And recoveries ranged from 95.8% to 99.8% with relative standard deviation less than 3.0%.


Assuntos
Impressão Molecular , Pontos Quânticos , Carbono , Cetirizina , Corantes Fluorescentes , Humanos , Limite de Detecção , Polímeros Molecularmente Impressos , Saliva , Dióxido de Silício
2.
J Infus Nurs ; 44(6): 315-322, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34555839

RESUMO

Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evaluated intravenous (IV) cetirizine 10 mg versus IV diphenhydramine 50 mg as pretreatment in patients receiving an anti-CD20 agent or paclitaxel. In the overall population (N = 34) and an elderly subgroup (n = 21), IV cetirizine was as effective as IV diphenhydramine in preventing infusion reactions (primary outcome) and associated with less sedation at all time points, a shorter infusion center stay, and fewer treatment-related adverse events.


Assuntos
Cetirizina , Urticária , Administração Intravenosa , Idoso , Cetirizina/efeitos adversos , Difenidramina/uso terapêutico , Humanos , Paclitaxel/efeitos adversos , Urticária/tratamento farmacológico
3.
Am J Physiol Renal Physiol ; 321(4): F466-F479, 2021 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-34423679

RESUMO

Intraurethral inoculation of mice with uropathogenic Escherichia coli (CP1) results in prostate inflammation, fibrosis, and urinary dysfunction, recapitulating some but not all of the pathognomonic clinical features associated with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). In both patients with LUTS and CP1-infected mice, we observed increased numbers and activation of mast cells and elevated levels of prostate fibrosis. Therapeutic inhibition of mast cells using a combination of a mast cell stabilizer, cromolyn sodium, and the histamine 1 receptor antagonist cetirizine di-hydrochloride in the mouse model resulted in reduced mast cell activation in the prostate and significant alleviation of urinary dysfunction. Treated mice showed reduced prostate fibrosis, less infiltration of immune cells, and decreased inflammation. In addition, as opposed to symptomatic CP1-infected mice, treated mice showed reduced myosin light chain-2 phosphorylation, a marker of prostate smooth muscle contraction. These results show that mast cells play a critical role in the pathophysiology of urinary dysfunction and may be an important therapeutic target for men with BPH/LUTS.NEW & NOTEWORTHY LUTS-associated benign prostatic hyperplasia is derived from a combination of immune activation, extracellular matrix remodeling, hyperplasia, and smooth muscle cell contraction in prostates of men. Using a mouse model, we describe the importance of mast cells in regulating these multiple facets involved in the pathophysiology of LUTS. Mast cell inhibition alleviates both pathology and urinary dysfunction in this model, suggesting the potential for mast cell inhibition as a therapeutic that prevents and reverses pathology and associated symptomology.


Assuntos
Fibrose/patologia , Mastócitos/fisiologia , Miócitos de Músculo Liso/patologia , Doenças Prostáticas/patologia , Animais , Antialérgicos/uso terapêutico , Cetirizina/uso terapêutico , Cromolina Sódica/uso terapêutico , Escherichia coli , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/metabolismo , Infecções por Escherichia coli/patologia , Fibrose/metabolismo , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Miócitos de Músculo Liso/metabolismo , Próstata/metabolismo , Próstata/patologia , Doenças Prostáticas/metabolismo , Micção
5.
Ann Allergy Asthma Immunol ; 127(4): 488-495.e5, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34186172

RESUMO

BACKGROUND: Birch pollen is a prevalent aeroallergen during the springtime allergy season. In field studies, variable allergen exposure and environmental factors can affect data quality while environmental exposure units (EEUs) deliver controlled, standardized, and reproducible allergen exposures. OBJECTIVE: To inform study design for EEU trials evaluating antiallergic therapies. METHODS: In this prospective study, 76 participants with birch allergy experienced 3 exposures to birch pollen: (1) an out-of-season EEU challenge (two 3-hour sessions on consecutive days); (2) a natural seasonal exposure; and (3) an in-season EEU challenge (3-hour exposure for 2 weeks after birch pollen season initiation). RESULTS: The total nasal symptom score, total ocular symptom score, and total symptom score (TSS = total nasal symptom score plus total ocular symptom score) were assessed every 30 minutes and daily during EEU and natural exposures. A high association between TSSs and day 2 of the out-of-season and in-season EEU challenges was noted, with a good association between the maximum TSS during the natural and in-season EEU challenges, and natural season and day 2 of the out-of-season EEU challenge (P < .001 for all). Participants had higher maximum change from the baseline TSS during day 2 of the out-of-season EEU challenge (12.4) vs the following: (1) first day (9.8); (2) in-season EEU challenge (8.4); and (3) natural seasonal exposure (7.6) (P < .001 for all). CONCLUSION: A strong association was seen between the presence of allergy symptoms and exposure to birch pollen in the EEU (maximum change in symptom scores during day 2) and in the field. A hybrid trial design may be useful to demonstrate the clinical efficacy of novel antiallergic therapies requiring fewer participants and shorter timelines and expediting treatment availability.


Assuntos
Antialérgicos/uso terapêutico , Betula/imunologia , Exposição Ambiental/efeitos adversos , Pólen/imunologia , Rinite Alérgica Sazonal/tratamento farmacológico , Adulto , Alérgenos/administração & dosagem , Alérgenos/imunologia , Cetirizina/uso terapêutico , Feminino , Humanos , Masculino , Furoato de Mometasona/uso terapêutico , Cloridrato de Olopatadina/uso terapêutico , Estudos Prospectivos , Rinite Alérgica Sazonal/imunologia , Estações do Ano , Índice de Gravidade de Doença
6.
Pediatr Allergy Immunol ; 32(7): 1533-1558, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-33894089

RESUMO

BACKGROUND: H1-antihistamines (AHs) are widely used for the treatment of allergic diseases, being one of the most commonly prescribed classes of medications in pediatrics. Newer-generation AHs are associated with fewer adverse effects compared with first-generation AHs. However, their relative harms in the pediatric population still need scrutiny. METHODS: We performed a systematic review of randomized controlled trials (RCTs), which included comparisons of safety parameters between an orally administered newer-generation AH and another AH (first- or second-generation), montelukast, or placebo in children aged ≤12 years. We searched MEDLINE and CENTRAL, independently extracted data on study population, interventions, adverse events (AEs), and treatment discontinuations, and assessed the methodologic quality of the included RCTs using the Cochrane's risk of bias tool. RESULTS: Forty-five RCTs published between 1989 and 2017 met eligibility criteria. The majority of RCTs included school-aged children with allergic rhinitis and had a follow-up period of up to a month. Four RCTs reported serious AEs in patients receiving a newer-generation AH, but only two patients experienced a possibly drug-related serious AE. The occurrence of AEs, drug-related AEs, and treatment discontinuations due to AEs varied between RCTs. Most AEs reported were of mild intensity. Indirect evidence indicates that cetirizine is more sedating than the other newer-generation AHs. CONCLUSION: Our findings confirm that newer-generation AHs have a favorable safety and tolerability profile. However, we could not draw firm conclusions regarding the comparative safety profile of the newer-generation AHs due to the paucity of head-to-head RCTs, variation in definitions and reporting of AEs, and short follow-up duration.


Assuntos
Antagonistas dos Receptores Histamínicos , Antagonistas dos Receptores Histamínicos H1 , Cetirizina/efeitos adversos , Criança , Humanos
7.
Colomb Med (Cali) ; 52(1): e7014577, 2021 Mar 18.
Artigo em Inglês | MEDLINE | ID: mdl-33911322

RESUMO

Case description: 32-month-old boy, IgG positive for SARS-CoV-2, presented to the emergency department with dermatologic lesions. Clinical findings: Four days before admission, he presented skin eruptions with redness and pruritus on hands and feet. Generalized papular erythema was evidenced, upper extremities with diffuse erythematosquamous plaques, palmoplantar keratoderma, so he was evaluated by a dermatologist who diagnosed pityriasis rubra pilaris. Treatment and outcome: rehydrating cream, cetirizine 0.5 mg/kg/day every two days, and prednisolone 2 mg/kg/day in the morning. He was discharged after 14 days, the patient presented clinical improvement, but the erythematous lesion persisted on the trunk and extremities. In the evaluation, after three months, the patient did not show the described lesions, evidencing an improvement and clinical resolution of the dermatological problems. Clinical relevance: We report a patient with pityriasis rubra piloris associated with a post-infection by SARS-CoV-2 that had not been described before.


Assuntos
COVID-19/complicações , Pitiríase Rubra Pilar/etiologia , Cetirizina/administração & dosagem , Pré-Escolar , Glucocorticoides/administração & dosagem , Humanos , Imunoglobulina G , Masculino , Pitiríase Rubra Pilar/diagnóstico , Pitiríase Rubra Pilar/tratamento farmacológico , Prednisolona/administração & dosagem
9.
Artigo em Inglês | MEDLINE | ID: mdl-33580925

RESUMO

Darier disease (DD) is a rare type of inherited keratinizing disorder with no definitive therapeutic approach. The objective of this study is to provide a detailed literature review of all the available treatment modalities of Darier disease, including those that are both surgical and non surgical, to compare their efficacies and to propose a novel therapeutic approach. A complete search of the literature for all articles describing the different treatments of Darier disease, with no restrictions on patients' ages, gender or nationalities, was performed with the use of PubMed. A total of 68 articles were included in the study: 3 prospective studies, 44 case reports/case series and 21 letters/correspondences/clinical images. The treatments described were topical, oral or physical. Retinoids (isotretinoin, tazarotene and adapalene) and fluorouracil were the two most effective topical treatments. Oral retinoids were the most effective oral therapy and were prescribed in the cases of generalized Darier disease. For localized and resistant skin lesions, physical therapies including surgical excision, dermabrasion and CO2 laser ablation were the first line choices. Limitations of this article include the inability to verify the accuracy of the published data, the relatively small sample size, the absence of randomized controlled clinical trials and possible unidentified confounding factors in various studies. In every therapeutic approach to Darier disease, consideration of patient comorbidities, disease distribution, severity and treatment accessibility is essential. Large and randomized clinical trials are necessary for the comparison of the efficacy and the safety of all the treatments of Darier disease and settling a consensus for management.


Assuntos
Doença de Darier/terapia , Administração Tópica , Algoritmos , Toxinas Botulínicas , Cetirizina/uso terapêutico , Ciclosporina/uso terapêutico , Dermabrasão , Diclofenaco/uso terapêutico , Di-Hidroxicolecalciferóis/uso terapêutico , Doxiciclina/uso terapêutico , Combinação de Medicamentos , Eletrocirurgia , Etinilestradiol/uso terapêutico , Ácidos Graxos/uso terapêutico , Fluoruracila/uso terapêutico , Glucocorticoides/uso terapêutico , Humanos , Lasers , Levanogestrel/uso terapêutico , Cloreto de Magnésio/uso terapêutico , Naltrexona/uso terapêutico , Fotoquimioterapia , Retinoides/uso terapêutico , Tacrolimo/uso terapêutico
10.
J Chromatogr Sci ; 59(10): 923-927, 2021 Oct 29.
Artigo em Inglês | MEDLINE | ID: mdl-33621328

RESUMO

A simple, accurate and precise RP-HPLC method was developed for the simultaneous determination of chloroquine, pyrimethamine and cetirizine hydrochloride concentrations in bulk drug and human serum. The assay was performed using a mobile phase of methanol: water (70:30) at pH of 2.8 ± 0.05 on the Purospher C-18 column with UV detection at 230 nm and rosuvastatin used as an internal standard. The retention times observed for chloroquine, pyrimethamine and cetirizine hydrochloride were 3.5, 2.5 and 5.5 minutes, respectively. The method was found to be specific for the assayed drugs showing a linear response in the concentration range of 1-100 µg mL-1 with coefficients of determination values of (r = 0.999). The method was developed and validated according to ICH guidelines. The method was used to monitor the serum samples and was found to be sensitive for therapeutic purposes, showing the potential to be a useful tool for routine analysis in laboratories.


Assuntos
Cetirizina , Pirimetamina , Cloroquina , Cromatografia Líquida de Alta Pressão , Humanos , Reprodutibilidade dos Testes
11.
BMJ Case Rep ; 14(2)2021 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-33547112

RESUMO

We describe a case of a young man, taking no other routine medications, presenting with erythema multiforme and cetirizine-induced psychosis with re-challenge evidence. On retrospective elicitation of history, it was found that he had been involved in a motor vehicle collision 4 months prior and was a daily cannabis user; there were no objective abnormalities by MRI and neurological evaluations. Although rare, cetirizine-induced psychosis is an important adverse drug reaction that warrants the attention of healthcare practitioners.


Assuntos
Antialérgicos/efeitos adversos , Cetirizina/efeitos adversos , Eritema Multiforme/tratamento farmacológico , Transtornos Psicóticos/etiologia , Adulto , Humanos , Masculino
12.
J Cosmet Dermatol ; 20(4): 1154-1159, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33417284

RESUMO

BACKGROUND: Androgenetic alopecia (AGA) is the most common form of alopecia in men. Cetirizine, a second-generation H1 blocker, is known for its anti-inflammatory properties and its ability to decrease prostaglandin D2 (PGD2) production. AIM: To evaluate the efficacy and tolerability of topical cetirizine in male patients with AGA. METHODS: Two groups of 30 patients each (healthy males aged between 22 and 55 years) with different grades of AGA classified according to the Hamilton-Norwood classification were recruited for this study. Group A subjects applied 1 mL of 1% topical cetirizine daily, while group B subjects served as controls and were instructed to apply 1 mL of a placebo solution for 6 months. RESULTS: Dermoscopic assessment revealed significantly higher hair regrowth among the cetirizine-treated group (P < .001). The patients' satisfaction was significantly higher among the cetirizine-treated group (P < .001). CONCLUSION: The current study highlights a potential role cetirizine might have in treating AGA. It should be noted that studies are lacking in this regard and more randomized and controlled trials are warranted in order to confirm or refute such early findings.


Assuntos
Cetirizina , Minoxidil , Administração Tópica , Adulto , Alopecia/tratamento farmacológico , Cetirizina/efeitos adversos , Cabelo , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
13.
J Clin Sleep Med ; 17(1): 99-101, 2021 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-32946371

RESUMO

NONE: Sleep terrors are a type of sleep disorder that is classified as parasomnias and is more common in children than in adults. Cetirizine is a histamine H1 antagonist that is US Food and Drug Administration approved for the treatment of allergic rhinitis and urticaria and has common adverse effects of drowsiness and headaches. We present a case of an adult man with a history of chronic sleep terror disorder and allergic rhinitis who developed worsening of his sleep terrors after initiation of cetirizine that subsequently resolved after discontinuing cetirizine and starting paroxetine.


Assuntos
Terrores Noturnos , Parassonias , Rinite Alérgica , Urticária , Adulto , Cetirizina/efeitos adversos , Humanos , Masculino , Rinite Alérgica/complicações , Rinite Alérgica/tratamento farmacológico , Estados Unidos
14.
Luminescence ; 36(3): 674-683, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33179404

RESUMO

A simple and sensitive flow injection-chemiluminescence (FI-CL) method was developed for determination of cetirizine dihydrochloride (CTZH) in pharmaceuticals. The method is primarily based on the enhancement effect of CTZH on the tris(2,2'-bipyridyl)ruthenium (II)-diperiodatoargentate (III) ([Ru(bpy)3 ]2+ -Ag(III) complex) CL system in an acidic medium. The optimum investigated variables of the CL reaction were: [Ru(bpy)3 ]2+ , 50 × 10-6 mol/L; sulfuric acid, 1.0 × 10-3 mol/L; Ag(III) complex, 100 × 10-6 mol/L; potassium hydroxide, 1.0 × 10-3 mol/L; flow rate, 3.0 ml/min and sample loop volume, 300 µl. The detection and quantification limits were 2.0 × 10-4 and 5.0 × 10-4 mg/L (S/N of 3 and 10) respectively with a linear calibration range of 5.0 × 10-4 to 7.5 mg/L (R2 = 0.9999, n = 11), injection throughput of 110/h and the relative standard deviations of 1.5-3.5% over the range studied. The methodology was successfully applied to determine CTZH in different pharmaceutical samples and validated with a high-performance liquid chromatography method, and resulted in the recovery of 94.6-108.6%. The probable CL reaction mechanism is described in brief.


Assuntos
Preparações Farmacêuticas , Rutênio , 2,2'-Dipiridil , Cetirizina , Análise de Injeção de Fluxo , Luminescência , Medições Luminescentes , Prata
15.
J Oncol Pharm Pract ; 27(2): 460-463, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32529951

RESUMO

INTRODUCTION: Recently CDK4/6 inhibitors have been introduced for the treatment of hormone positive breast cancer resistant to endocrine therapy. Among their side effects, alopecia is often reported being associated to patients' distress and depressive symptoms. CASE REPORT: We report the case of a 70-year-old woman affected by breast cancer in treatment with Palbociclib, who developed alopecia.Management and Outcome: We prescribed a topical solution with cetirizine. Global photography, trichoscopy and trichogram were assessed. All evaluations demonstrated alopecia improvement. DISCUSSION: Currently, no treatment options for CDK 4/6 inhibitors induced alopecia have been proposed. Herein, we report the use of topical cetirizine.


Assuntos
Alopecia/induzido quimicamente , Alopecia/tratamento farmacológico , Antineoplásicos/efeitos adversos , Cetirizina/uso terapêutico , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Piperazinas/efeitos adversos , Inibidores de Proteínas Quinases/efeitos adversos , Piridinas/efeitos adversos , Administração Tópica , Idoso , Neoplasias da Mama/complicações , Neoplasias da Mama/tratamento farmacológico , Cetirizina/administração & dosagem , Quinases Ciclina-Dependentes/antagonistas & inibidores , Feminino , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Humanos , Metástase Neoplásica/tratamento farmacológico , Piperazinas/uso terapêutico , Inibidores de Proteínas Quinases/uso terapêutico , Piridinas/uso terapêutico , Couro Cabeludo/patologia , Resultado do Tratamento
18.
Med Hypotheses ; 144: 110046, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-33254480

RESUMO

It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), another two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV.


Assuntos
Acetatos/uso terapêutico , Antivirais/uso terapêutico , COVID-19/tratamento farmacológico , Cetirizina/uso terapêutico , Reposicionamento de Medicamentos , Quinolinas/uso terapêutico , Antiasmáticos/uso terapêutico , Ensaios Clínicos como Assunto , Antagonistas não Sedativos dos Receptores H1 da Histamina/uso terapêutico , Humanos , Hipersensibilidade/tratamento farmacológico , Modelos Teóricos , Segurança do Paciente , Paladar
19.
Allergy Asthma Proc ; 41(6): 449-453, 2020 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-33109311

RESUMO

Background: Ocular allergies affect an estimated 40% of the population, 98% of which are because of allergic conjunctivitis and includes tear film dysfunction. With the current advent of both repurposed drugs for ocular allergies, as well as novel drugs, lubricants and methods of administration, there is a need to update new treatments to optimize the care of ocular allergy patients. Methods: An overview of mediators, clinical characteristics and management is provided in a summary format. Results: Lubricants (best when refrigerated provide immediate relief that is short lived (several minutes) due to its dilutional effect on mediators and pollen in the tear film. Immediate and longer-term benefit occurs from different topical and oral medications - primarily histamine receptor agonists. Conclusion: The newest prescription topical ophthalmic histamine H1 receptor antagonist (an inverse agonist) to be approved by the U.S. Food and Drug Administration in the past 10 years (U.S. NDA approved May 30, 2017) is cetirizine ophthalmic solution for the treatment of ocular itching with allergic conjunctivitis in adults and in children more than 2 years old.


Assuntos
Cetirizina/uso terapêutico , Conjuntivite Alérgica/imunologia , Olho/patologia , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Hipersensibilidade/imunologia , Inflamação/imunologia , Uveíte Anterior/imunologia , Adulto , Criança , Conjuntivite Alérgica/tratamento farmacológico , Humanos , Hipersensibilidade/tratamento farmacológico , Inflamação/tratamento farmacológico , Uveíte Anterior/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...